Bibliographic Details
| Title: |
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study |
| Authors: |
Lucia Taramasso, Antonio Falletta, Elena Ricci, Giancarlo Orofino, Nicola Squillace, Barbara Menzaghi, Giuseppe Vittorio De Socio, Chiara Molteni, Giovanni Francesco Pellicanò, Roberto Gulminetti, Giordano Madeddu, Eleonora Sarchi, Francesca Vichi, Benedetto Maurizio Celesia, Paolo Bonfanti, Antonio Di Biagio |
| Source: |
Viruses, Vol 14, Iss 11, p 2315 (2022) |
| Publisher Information: |
MDPI AG, 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Microbiology |
| Subject Terms: |
dolutegravir, two-drug regimen, three-drug regimen, ART, immune recovery, CD4/CD8 ratio, Microbiology, QR1-502 |
| More Details: |
The aim of the present study was to evaluate CD4/CD8 dynamics in patients on dolutegravir (DTG)-based two-drug regimens (2DRs) and compare them with DTG-containing triple-drug regimens (3DRs). A prospective observational study was performed in the context of the SCOLTA cohort. Experienced PWH with HIV-RNA < 50 copies/mL were included if they were on the DTG-2DR, the DTG + tenofovir/emtricitabine (TDF/FTC) regimen, the DTG + tenofovir alafenamide (TAF)/FTC regimen, or the DTG + abacavir/lamivudine (ABC/3TC) regimen; they were followed-up for at least one year. A total of 533 PWH were enrolled, 120 in the DTG + 3TC group, 38 in the DTG + protease inhibitors (PI) group, 67 in the DTG + rilpivirine (RPV) group, 49 in the DTG + TDF/FTC group, 27 in the DTG + TAF/FTC group, and 232 in the DTG + ABC/3TC group. After one year, the CD4/CD8 ratio significantly increased in the PWH treated with DTG + 3TC (+0.08 ± 0.26), DTG + TDF/FTC (+0.1 ± 0.19), and DTG + ABC/3TC (+0.08 ± 0.25). At two years, the CD4/CD8 increase was confirmed for PWH on DTG + TDF/FTC (+0.16 ± 0.28) and DTG + ABC/3TC (+0.1 ± 0.3). In the SCOLTA cohort, PWH on 2DRs experienced a CD4/CD8 increase only in the DTG + 3TC group. Controlled studies with longer follow-up will clarify the long-term immunological and clinical impacts of DTG-2DR. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1999-4915 |
| Relation: |
https://www.mdpi.com/1999-4915/14/11/2315; https://doaj.org/toc/1999-4915 |
| DOI: |
10.3390/v14112315 |
| Access URL: |
https://doaj.org/article/006f8d3867864375a6f92cdb7cc04b84 |
| Accession Number: |
edsdoj.006f8d3867864375a6f92cdb7cc04b84 |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
